Themis Medicare Faces Financial Challenges Amidst Strong Cash Flow and Dividend Payout

Themis Medicare, a small-cap player in the Pharmaceuticals and Biotechnology sector, has recently undergone a financial trend adjustment reflecting its current performance metrics. The company reported a negative financial performance for the quarter ending September 2025, with its score showing a notable change over the past three months.
On the positive side, Themis Medicare achieved its highest operating cash flow at Rs 34.71 crore and a strong dividend payout ratio of 19.24%. However, several key indicators reveal challenges for the company. The profit before tax (PBT) from other income has significantly declined to Rs -6.69 crore, marking a substantial drop compared to the previous four-quarter average. Additionally, the profit after tax (PAT) stands at Rs -3.62 crore, down by 59.6%. Other concerning metrics include a decrease in net sales to Rs 77.99 crore, a return on capital employed (ROCE) of -3.47%, and a low cash and cash equivalents figure of Rs 12.75 crore.

In terms of market performance, Themis Medicare's stock has faced considerable challenges over various time frames. Year-to-date, the stock has declined by 55.46%, contrasting sharply with the Sensex's 7.97% gain. Over the past year, the stock has dropped by 57.69%, while the Sensex has risen by 8.74%. Despite a positive return over three, five, and ten years, the recent performance highlights the need for strategic adjustments to align with market expectations.